ICHNO 2026 Presentation - Therapeutic Cancer vaccine abipapogene suvaplasmid (VB10.16) plus pembrolizumab as 1L treatment for HPV16-positive, PD-L1-positive r/m oropharyngeal cancer. A phase 1 dose-escalation trial